Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.

Maarten OomsSofie CelenRonald De HoogtIlse LenaertsJohnny LiebregtsGreet VanhoofXavier LangloisAndrey PostnovMichel KooleAlfons VerbruggenKoen Van LaereGuy Bormans

Published in: EJNMMI radiopharmacy and chemistry (2016)

Repeated D-amphetamine treatment significantly increased PDE10A binding, which is not observed upon selective D1 receptor blocking. This study suggests a potential pharmacological interaction between PDE10A enzymes and drugs modifying DA neurotransmission. Therefore, PDE10A binding in patients with neuropsychiatric disorders might be modulated by chronic DA-related treatment.

Keyphrases

binding protein
metabolic syndrome
dna binding
smoking cessation